Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 3/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.45 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | FRK | P42685 | 1/20 | 0.37 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.37 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 7/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639200 | 0.87 | CLK1 (0.45) | DYRK1ACLK1FRKCAMK2BCAMK2G | |
| SCHEMBL3641215 | 0.86 | MAPT (0.44) | DYRK1ACLK1FRKCAMK2BCAMK2G | |
| SCHEMBL3640872 | 0.86 | HDAC1 (0.43) | DYRK1ACLK1FRKCAMK2BCAMK2G | |
| SCHEMBL3636650 | 0.85 | ERBB2 (0.43) | FRKCAMK2BCAMK2GCAMK2DGCGR | |
| SCHEMBL3639540 | 0.84 | HDAC1 (0.47) | DYRK1ACLK1FRKCAMK2BCAMK2G | |
| SCHEMBL3634547 | 0.84 | CLK1 (0.46) | DYRK1ACLK1FRKCAMK2BCAMK2G | |
| SCHEMBL3635158 | 0.82 | MAPT (0.44) | DYRK1ACLK1GCGRTRPV1MAPT | |
| SCHEMBL3639603 | 0.82 | P2RX1 (0.42) | DYRK1ACLK1FRKCAMK2BCAMK2G | |
| SCHEMBL3637862 | 0.81 | ERBB2 (0.43) | FRKCAMK2BCAMK2GCAMK2DBRD4 | |
| SCHEMBL3637523 | 0.81 | CLK1 (0.41) | DYRK1ACLK1FRKCAMK2BCAMK2G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | disclosed |
| EP-2167464-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | Abbott GmbH & Co. KG (DE) | 2010-03-31 | — | — | EP | disclosed |
| CN-101687790-A | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2(MGLU2 receptor) | ABBOTT GMBH & CO KG | 2010-03-31 | — | — | CN | disclosed |
| WO-2008145616-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | ABBOTT GMBH & CO. KG (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | GRM2, GRIN2C, GRM1 | KCNQ3 487/4885KCNQ2 405/4885KCNQ1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.